GLP ‐1 Receptor Agonists for Treating Alcohol Use Disorder: A Critical Review
Open Access
- 18 May 2026
- journal article
- review article
- Published by Wiley in Alcohol, Clinical and Experimental Research
- Vol. 50 (5) , e70312
Abstract
This narrative review evaluates glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) as potential treatments for alcohol use disorder (AUD), a major public health problem with limited treatment options. We first briefly describe the development of GLP‐1RAs for treating type 2 diabetes and obesity and then focus on recent studies of the drugs' effects on alcohol‐related behaviors, both in animal models and clinical studies. We identified relevant literature by searching for studies of incretin‐based therapies using PubMed, Google Scholar, and clinicaltrials.gov and reviewing the reference lists of published reviews. We limited our discussion of preclinical studies of alcohol‐related effects to those that provide insights into the mechanism of effects. Clinical studies comprised both observational studies, including those using electronic health records and other real‐world data, and randomized controlled clinical trials, including studies completed or in progress. Of the clinical studies, we include original, peer‐reviewed research published in English and excluded case reports, commentaries, and preprints. This yielded a total of 13 preclinical studies, 14 clinical studies, 4 published interventional trials, and 19 interventional trials in progress or completed but unpublished. We found convergent evidence from animal and human studies that GLP‐1RAs reduce alcohol consumption and improve alcohol‐associated outcomes. Several randomized controlled trials (RCTs) in progress aim to test the effects of both established and novel compounds, and different drug formulations and combinations on alcohol consumption. Additional RCTs are needed to establish the efficacy of GLP‐1RAs for treating AUD, with mechanistic studies needed to elucidate more fully their mode of action in reducing alcohol consumption.Keywords
This publication has 66 references indexed in Scilit:
- Long-term treatment with a glucagon-like peptide-1 receptor agonist reduces ethanol intake in male and female ratsTranslational Psychiatry, 2020
- Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1–7 trialsDiabetes & Metabolism, 2019
- Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trialThe Lancet Diabetes & Endocrinology, 2019
- Central GLP-1 receptors: Novel molecular targets for cocaine use disorderPhysiology & Behavior, 2019
- Effects of glucagon-like peptide 1 analogs on alcohol intake in alcohol-preferring vervet monkeysPsychopharmacology, 2018
- The glucagon‐like peptide 1 receptor agonist liraglutide attenuates the reinforcing properties of alcohol in rodentsAddiction Biology, 2015
- The Glucagon-Like Peptide 1 Analogue Exendin-4 Attenuates the Nicotine-Induced Locomotor Stimulation, Accumbal Dopamine Release, Conditioned Place Preference as well as the Expression of Locomotor Sensitization in MicePLOS ONE, 2013
- The Glucagon-Like Peptide 1 Analogue, Exendin-4, Attenuates the Rewarding Properties of Psychostimulant Drugs in MicePLOS ONE, 2013
- Systematic Review: Effect of Alcohol Intake on Adherence to Outpatient Medication Regimens for Chronic DiseasesJournal of Studies on Alcohol and Drugs, 2012
- Alcohol’s Role in Gastrointestinal Tract Disorders1997